Paget's Disease News and Research

RSS
Paget’s disease of the bone is a chronic ailment affecting the skeleton. Sir James Paget described Paget's disease of bone in 1877 and the disease is named after him. This is a rare disease affecting 1% of the population in the United States. It commonly affects the elderly and nearly 3 to 4% of the population over age 50 are affected.
Research findings suggest potential strategies to combat IBMPFD and other degenerative diseases

Research findings suggest potential strategies to combat IBMPFD and other degenerative diseases

New article shows taxonomic classification of rare genetic bone disorders based on metabolic phenotypes

New article shows taxonomic classification of rare genetic bone disorders based on metabolic phenotypes

Shire announces availability of Natpara (parathyroid hormone) for injection in U.S.

Shire announces availability of Natpara (parathyroid hormone) for injection in U.S.

Endocrine Society issues Clinical Practice Guideline on rare bone condition

Endocrine Society issues Clinical Practice Guideline on rare bone condition

Researchers discover link between NOX4 enzyme and osteoporosis

Researchers discover link between NOX4 enzyme and osteoporosis

VCP gene mutations cause neurological conditions including IBMPFD and ALS

VCP gene mutations cause neurological conditions including IBMPFD and ALS

Study identifies how new ALS gene mutations cause other diseases of the brain, muscle and bone

Study identifies how new ALS gene mutations cause other diseases of the brain, muscle and bone

Osteoporosis medication Aclasta now available on Canadian public drug plans

Osteoporosis medication Aclasta now available on Canadian public drug plans

New mouse model could foster ALS, Paget's and dementia breakthroughs

New mouse model could foster ALS, Paget's and dementia breakthroughs

FDA reviews safety issues of bisphosphonates for osteoporosis

FDA reviews safety issues of bisphosphonates for osteoporosis

Eli Lilly, Synthes collaborate to develop osteoinductive products

Eli Lilly, Synthes collaborate to develop osteoinductive products

Bone building drugs bisphosphonates lead to only a marginally higher risk of fractures: Study

Bone building drugs bisphosphonates lead to only a marginally higher risk of fractures: Study

IOF, ANZBMS to hold osteoporosis and bone meeting in Asia-Pacific region

IOF, ANZBMS to hold osteoporosis and bone meeting in Asia-Pacific region

State court jury rules in favor of Merck in FOSAMAX trial

State court jury rules in favor of Merck in FOSAMAX trial

New study reveals measles viral gene plays key role in development of PD

New study reveals measles viral gene plays key role in development of PD

TransPharma reports positive results from ViaDerm-Calcitonin Phase 1 trial for musculoskeletal disorders

TransPharma reports positive results from ViaDerm-Calcitonin Phase 1 trial for musculoskeletal disorders

Kanis receives Hamdan Award for Medical Research Excellence in osteoporosis

Kanis receives Hamdan Award for Medical Research Excellence in osteoporosis

Merck wins third FOSAMAX bellwether trial

Merck wins third FOSAMAX bellwether trial

Novartis announces six-year data of Reclast injection for postmenopausal women with osteoporosis

Novartis announces six-year data of Reclast injection for postmenopausal women with osteoporosis

New data on Merck’s odanacatib for osteoporosis in postmenopausal women presented at 32nd ASBMR

New data on Merck’s odanacatib for osteoporosis in postmenopausal women presented at 32nd ASBMR